Comparison of Efficacy of Botulinum Toxin Injection and Conventional Oral Drugs for Treatment of Refractory Migraine
Article Sidebar
Main Article Content
Abstract
Background: Background: Migraine, a debilitating neurological condition, significantly impacts quality of life. Despite various treatments, some cases remain refractory to conventional therapies. This study explores the efficacy of Botulinum Toxin Type A (BOTOX) injections compared to Conventional Oral Drugs (CODs) in treating refractory migraines, offering potential advancements in migraine management.
Objectives: This single-center retrospective cohort study compared the efficacy and safety of Botulinum toxin (BOTOX) injection and Conventional Oral Drugs (COD) for treating the refractory migraine.
Methods: Between May and August of 2023, 78 adults with refractory migraine were enrolled at tertiary care center in Islamabad. Their demographic data revealed the mean age of 46.5 years (SD=10.09), gender distribution of 28 males (35.90%) and 50 females (64.10%), and distribution of 27 employed (34.61%) and 51 unemployed (65.30%).
Results: Average duration of refractory migraines was 9.72 years and average number of migraines per month was 22. The number of headache days per month decreased from 22 at baseline to 19 after two months and to 12 after three months (p=0.239) as the primary outcome measure (p>0.05). The VAS scores decreased substantially from 7.6 to 5.5 (p=0.049), indicating decrease in headache severity (p<0.05). Scores on Migraine-Specific Quality of Life (MSQ) increased from 43 to 73% (p>0.05). The Migraine Disability Assessment (MIDAS) scores decreased from 66 to 48 (p=0.047) and Headache Impact Test (HIT-6) scores decreased from 69 to 40 (p=0.025), indicating an improvement in disability and quality of life (p<0.05). Injection site pain (n=35), nausea (n=25), dizziness (n=15), fatigue (n=12), parched mouth (n=5), and muscle weakness (n=5) were reported as adverse effects.
Conclusion: While BOTOX treatment significantly improved measures of headache severity, disability, and quality of life, patient tolerability and potential distress must be considered when selecting this treatment.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
D'Antona L, Matharu M. Identifying and managing refractory migraine: barriers and opportunities? J Headache Pain. 2019 Aug 23;20(1):89. doi: 10.1186/s10194-019-1040- x.
Gupta J, Gaurkar SS. Migraine: An Underestimated Neurological Condition Affecting Billions. Cureus. 2022 Aug 24;14(8):e28347. doi: 10.7759/cureus.28347.
Eigenbrodt AK, Ashina H, Khan S, Diener HC, Mitsikostas DD, Sinclair AJ, Pozo-Rosich P, Martelletti P, Ducros A, Lantéri-Minet M, Braschinsky M, Del Rio MS, Daniel O, Özge A, Mammadbayli A, Arons M, Skorobogatykh K, Romanenko V, Terwindt GM, Paemeleire K, Sacco S, Reuter U, Lampl C, Schytz HW, Katsarava Z, Steiner TJ, Ashina
M. Diagnosis and management of migraine in ten steps. Nat Rev Neurol. 2021 Aug;17(8):501-514. doi: 10.1038/s41582-021-00509-5.
Mungoven TJ, Henderson LA, Meylakh N. Chronic Migraine Pathophysiology and Treatment: A Review of Current Perspectives. Front Pain Res (Lausanne). 2021 Aug 25;2:705276. doi: 10.3389/fpain.2021.705276.
Martelletti P, Katsarava Z, Lampl C, Magis D, Bendtsen L, Negro A, Russell MB, Mitsikostas DD, Jensen RH. Refractory chronic migraine: a consensus statement on clinical definition from the European Headache Federation. J Headache Pain. 2014 Aug 28;15(1):47. doi: 10.1186/1129-2377-15-47.
Bussone G. Clinical considerations on chronic migraine, pharmacoresistance and refractoriness. Neurol Sci. 2010 Jun;31 Suppl 1:S83-5. doi: 10.1007/s10072-010-0294-5.
Shimizu T, Sakai F, Miyake H, Sone T, Sato M, Tanabe S, Azuma Y, Dodick DW. Disability, quality of life, productivity impairment and employer costs of migraine in the workplace. J Headache Pain. 2021 Apr 21;22(1):29. doi: 10.1186/s10194-021-01243-5.
Kępczyńska K, Domitrz I. Botulinum Toxin-A Current Place in the Treatment of Chronic Migraine and Other Primary Headaches. Toxins (Basel). 2022 Sep 5;14(9):619. doi: 10.3390/toxins14090619.
Sebastianelli G, Casillo F, Di Renzo A, Abagnale C, Cioffi E, Parisi V, Di Lorenzo C, Serrao M, Pierelli F, Schoenen J, et al. Effects of Botulinum Toxin Type A on the Nociceptive and Lemniscal Somatosensory Systems in Chronic Migraine: An Electrophysiological Study. Toxins. 2023; 15(1):76. https://doi.org/10.3390/ toxins15010076
Martinelli D, Pocora MM, De Icco R, Allena M, Vaghi G, Sances G, Castellazzi G, Tassorelli C. Searching for the Predictors of Response to BoNT-A in Migraine Using Machine Learning Approaches. Toxins. 2023; 15(6):364. https://doi.org/10.3390/ toxins15060364
Demaagd G. The pharmacological management of migraine, part 1: overview and abortive therapy. P T. 2008 Jul;33(7):404-16. PMID: 19750119; PMCID: PMC2740949.
Ramachandran R, Yaksh TL. Therapeutic use of botulinum toxin in migraine: mechanisms of action. Br J Pharmacol. 2014 Sep;171(18):4177-92. doi: 10.1111/ bph.12763.
Becker WJ. Botulinum Toxin in the Treatment of Headache. Toxins (Basel). 2020 Dec 17;12(12):803. doi: 10.3390/toxins12120803.
Frampton JE, Silberstein S. OnabotulinumtoxinA: A Review in the Prevention of Chronic Migraine. Drugs. 2018 Apr;78(5):589-600. doi: 10.1007/s40265-018-0894-6.
Negro A, Curto M, Lionetto L, Martelletti P. A two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache: a real-world experience. J Headache Pain. 2015;17:1. doi: 10.1186/s10194-016-0591-3.
Atraszkiewicz D, Ito R, Bahra A. The efficacy of botulinum toxin type-A for intractable chronic migraine patients with no pain-free time. Br J Pain. 2022 Feb;16(1):41-49. doi: 10.1177/20494637211014544.
Evers S, Vollmer-Haase J, Schwaag S, Rahmann A, Husstedt IW, Frese A. Botulinum toxin A in the prophylactic treatment of migraine--a randomized, double-blind, placebo- controlled study. Cephalalgia. 2004 Oct; 24 ( 10 ): 838 - 43 . doi: 10 . 1111 / j.1468-2982.2004.00754.x.
Lin KH, Chen SP, Fuh JL, Wang YF, Wang SJ. Efficacy, safety, and predictors of response to botulinum toxin type A in refractory chronic migraine: a retrospective study. J Chin Med Assoc. 2014 Jan;77(1):10-5. doi: 10.1016/j.jcma.2013.09.006.
Shaterian N, Shaterian N, Ghanaatpisheh A, Abbasi F, Daniali S, Jalali Jahromi M, Sanie MS, Abdoli A. Botox (OnabotulinumtoxinA) for Treatment of Migraine Symptoms: A Systematic Review. Pain Res Manag. 2022 Mar 31;2022:3284446. doi: 10.1155/2022/3284446. eCollection 2022. PMID: 35401888; PMCID: PMC8989603.